Search results
Results from the WOW.Com Content Network
A small percentage of HIV-1 infected individuals retain high levels of CD4+ T-cells without antiretroviral therapy. However, most have detectable viral loads and will eventually progress to AIDS without treatment. These individuals are classified as HIV controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts and ...
Crofelemer (USAN, trade name Mytesi) is an antidiarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. [1] Other possible uses include diarrhea in children, acute infectious diarrhea , and diarrhea in patients with irritable bowel syndrome . [ 2 ]
Diarrhea is defined by the World Health Organization as having three or more loose or liquid stools per day, or as having more stools than is normal for that person. [2] Acute diarrhea is defined as an abnormally frequent discharge of semisolid or fluid fecal matter from the bowel, lasting less than 14 days, by World Gastroenterology ...
Gastrointestinal biotech firm Salix Pharmaceuticals announced Wednesday that the Food and Drug Administration has approved Fulyzaq, the company's orally taken diarrhea treatment for patients ...
With improvements in HIV therapy, several studies now estimate that patients on treatment in high-income countries can expect a normal life expectancy. [ 69 ] [ 70 ] This means that a higher proportion of people living with HIV are now older and research is ongoing into the unique aspects of HIV infection in the older adult.
[5] [12] An HIV-positive person on treatment can expect to live a normal life, and die with the virus, not of it. [13] [12] Effective treatment for HIV-positive people (people living with HIV) involves a life-long regimen of medicine to suppress the virus, making the viral load undetectable.
The most common adverse events with didanosine are diarrhea, nausea, vomiting, abdominal pain, fever, headache, and rash. [4] Peripheral neuropathy occurred in 21-26% of participants in key didanosine trials. [5] Pancreatitis is rarely observed but has caused occasional fatalities, and has black box warning status. [6]
AIDS-related complex (ARC) was introduced after discovery of the HIV (human immunodeficiency virus) when the medical community became aware of the inherent difficulties associated with treating patients who have an advanced case of HIV which gave rise to the term acquired immune deficiency syndrome (AIDS).